Commercial Lilly falls on slower start for Foundayo versus Wegovy PharmaphorumSky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.Metabolic & GLP-1Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum Sky-high expectations for sales of Eli Lilly’s new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UK biotech could be bound for recovery, BIA report revealsNext: New NIHR-funded TRC for Parkinson’s disease Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
